A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
About this study
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
- Condition
- Overweight, Obesity
- Tested
- Macupatide, Eloralintide, Placebo
- Sponsor
- Eli Lilly and Company
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Overweight, Obesity
- See Master Protocol CWMM (NCT06143956) for inclusion criteria
Exclusion 6
- In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):
- Have type 1 diabetes or type 2 diabetes
- Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
- Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
- Have a history of acute or chronic pancreatitis
- All concomitant medications should be at a stable dose for at least 3 months prior to screening
Where
40 sites, 40 recruiting
Dent Neurologic Institute
Amherst, New York, United States
Medical Research Partners
Ammon, Idaho, United States
IMA Clinical Research Austin
Austin, Texas, United States
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
and 34 more sites on ClinicalTrials.gov
Contact
-
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559 LillyTrials@Lilly.com
-
Physicians interested in becoming principal investigators please contact
Potential match only. Final eligibility is determined by the study team.